Europe

Takeda Pharmaceutical Company Limited announced that ALUNBRIG™ (brigatinib) has received Accelerated Approval from the U.S. Food and Drug Administration (FDA) for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under…
Intralytix, Inc. announced that the Company is partnering with BioPhage Therapeutics Limited to develop and commercialize topical bacteriophage treatments of human wounds infected or colonized with S. aureus. "Treatment of bacteria-infected wounds is one the most critical problems in modern medicine. Infected wounds complicate healing, often necessitate repeated surgical interventions,…
Ascendis Pharma A/S ,biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs in rare diseases announced data supporting its product pipeline presented at ENDO 2017, the annual meeting of the Endocrine Society in Orlando, Florida. "We are delighted to show the breadth of our growing…
Neurim Pharmaceuticals and Exeltis announced a license agreement in which Exeltis will obtain exclusive marketing rights for Neurim’s new Rx PedPRM in Spain. Neurim’s paediatric prolonged-release melatonin is an age-appropriate drug targeted to treat sleep disorders in children with autism spectrum disorders (ASD) and neurogenetic diseases. It is expected to…
To help address the challenges surrounding supply chain management for cell and gene therapy around the globe, Thermo Fisher Scientific, the world leader in serving science announced a collaboration with the Cell and Gene Therapy Catapult (CGT Catapult) to provide developers with both the manufacturing capability and distribution, logistics, and…
Page 1 of 22

Subscribe To Our Newsletter

Security Q:How many eyes has a typical person? (ex: 1)
Name:
Email: